Table 1 Tumor incidence in limiting dilution assay

From: Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

No. of cells injected

Tumor incidence

 

Placebo

ATO + ATRA

Parental

CRISPR

102

5/6

0/6

—

—

103

4/5

2/4

4/5

0/5

104

5/5

4/6

5/5

0/5

105

4/4

5/6

5/5

1/5

BCSC frequency

1 in 252

1 in 22,644

1 in 621

1 in 503,345

95% CI

1 in 88–1 in 722

1 in 8,220–1 in 62,382

1 in 209–1 in 1,847

1 in 71,332–1 in 3,551,801

  1. 231 xenografts from mice treated with placebo or ATO plus ATRA or parental or CRISPR 231 cells were dissociated into single-cell suspensions and injected into the flank of mice in limiting dilution. Tumor formation were observed for 6 weeks after inoculation. CSC frequency was calculated using the L-Calc software
Back to article page